Eisai Anticipates EU Decision on BioArctic's Lecanemab in Q2
核心洞察
Eisai anticipates a decision from the European Medicines Agency (搜索) (EMA) regarding marketing authorization for lecanemab in the second quarter of this year.
The EMA's Scientific Advisory Board is scheduled to convene in the first quarter to discuss the marketing authorization application for lecanemab.
BioArctic (搜索) and Eisai are jointly preparing for the commercialization of lecanemab in Nordic countries, pending European approval.
Eisai, partner of BioArctic (搜索), announced that the European Medicines Agency (搜索)'s (EMA) Scientific Advisory Board will meet to discuss the marketing authorization application for lecanemab (Leqembi). The advisory group meeting is expected to take place in the first quarter of this year.
Eisai anticipates a decision on marketing authorization in the second quarter of this year, contingent on receiving an opinion from the Committee for Medicinal Products for Human Use (CHMP) by March 31, following the Advisory Group discussion. BioArctic (搜索) has licensed lecanemab to Eisai in exchange for milestone payments and royalties on sales.
Currently, BioArctic (搜索) and Eisai are preparing for joint commercialization in the Nordic countries, pending European approval. Globally, Eisai collaborates with Biogen on the marketing and commercialization of lecanemab, sharing costs and potential profits equally. Lecanemab represents a significant advancement in Alzheimer's (搜索) treatment, targeting amyloid plaques (搜索) in the brain, a key pathological hallmark of the disease.